0001493152-23-033779.txt : 20230926
0001493152-23-033779.hdr.sgml : 20230926
20230926173428
ACCESSION NUMBER: 0001493152-23-033779
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230922
FILED AS OF DATE: 20230926
DATE AS OF CHANGE: 20230926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tapolczay David
CENTRAL INDEX KEY: 0001991789
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41245
FILM NUMBER: 231281400
MAIL ADDRESS:
STREET 1: 32 CROUCH HALL LANE
CITY: ST. ALBANS
STATE: X0
ZIP: AL3 7EU
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CONDUIT PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0001896212
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 873272543
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4995 MURPHY CANYON ROAD, SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92123
BUSINESS PHONE: (760) 471 8536
MAIL ADDRESS:
STREET 1: 4995 MURPHY CANYON ROAD, SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92123
FORMER COMPANY:
FORMER CONFORMED NAME: Murphy Canyon Acquisition Corp.
DATE OF NAME CHANGE: 20211130
3
1
ownership.xml
X0206
3
2023-09-22
0
0001896212
CONDUIT PHARMACEUTICALS INC.
CDT
0001991789
Tapolczay David
4995 MURPHY CANYON ROAD, SUITE 300
SAN DIEGO
CA
92123
1
1
0
0
Chief Executive Officer
Common Stock, par value $0.0001 per share
2003324
D
Includes 2,003,324 shares of common stock of the Company received pursuant to the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023, by and among the Company, Conduit Pharmaceuticals Limited, a Cayman Islands exempted company ("Conduit") and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly-owned subsidiary of MURF (the "Merger Sub"). As a result of, and upon consummation of the transactions contemplated by, the Merger Agreement, the Company changed its name from "Murphy Canyon Acquisition Corp." to "Conduit Pharmaceuticals Inc."
/s/ David Tapolczay
2023-09-26